Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a US-based speciality pharmaceutical company, announced on Monday that has signed a national co-promotion agreement with Verity Pharmaceuticals International Ltd, a Canada-based speciality pharmaceutical company, to support Cumberland's new Sancuso oncology support product.
According to a co-promotion partnership, Verity is to feature Sancuso across the United States via its established oncology commercial organisation and customer network.
Sancuso, the first and only FDA-approved prescription patch, is intended for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment.
Under the terms of the contract, Verity Pharmaceuticals is to promote Sancuso throughout most of the country via its national oncology sales organisation. Both firms will share in the incremental contribution margin resulting from Verity Pharmaceuticals' efforts.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML